跳至主要内容
临床试验/NCT02297958
NCT02297958已完成不适用

Impact of Fas/FasL in Chemotherapy Response in Epithelial Ovarian Carcinoma

Rennes University Hospital1 个研究点 分布在 1 个国家目标入组 28 人开始时间: 2015年1月15日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
28
试验地点
1
主要终点
Correlation between cleaved FasL level ans neoadjuvant chemotherapy tumor response

研究概览

简要总结

Ovarian carcinoma has poor prognosis and new therapeutic strategies are required. Many patients with ovarian carcinoma showed resistance to chemotherapy. Cleaved FasL is known for induced atypical response when is binding to Fas such as avoiding apoptosis and inducing cell motility.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Patient with suspicious ovarian carcinoma using clinical data, biological data (ca125) and radiological data (CT)
  • Inclusion Criteria:
  • Pathological ovarian carcinoma diagnosed at pathological analysis after surgery.
  • Neo adjuvant chemotherapy

排除标准

  • no neo-adjuvant chemotherapy
  • no ovarian carcinoma at final pathological analysis
  • less than 18 years old.

结局指标

主要结局

Correlation between cleaved FasL level ans neoadjuvant chemotherapy tumor response

时间窗: surgery

Main outcome is cleaved FasL level and correlation with neoadjuvant chemotherapy tumor response, evaluated during surgery.

次要结局

  • Disease Free Survival rate(18 months after surgery)
  • Identification of tumoral T cells(surgery)
  • Overall survival rate(18 months after surgery)

研究者

发起方
Rennes University Hospital
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验